These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 33382803

  • 1. Individual and community-level benefits of PrEP in western Kenya and South Africa: Implications for population prioritization of PrEP provision.
    Mudimu E, Peebles K, Mukandavire Z, Nightingale E, Sharma M, Medley GF, Klein DJ, Kripke K, Bershteyn A.
    PLoS One; 2020; 15(12):e0244761. PubMed ID: 33382803
    [Abstract] [Full Text] [Related]

  • 2. Time to Scale Up Preexposure Prophylaxis Beyond the Highest-Risk Populations? Modeling Insights From High-Risk Women in Sub-Saharan Africa.
    Grant H, Gomez GB, Kripke K, Barnabas RV, Watts C, Medley GF, Mukandavire Z.
    Sex Transm Dis; 2020 Nov; 47(11):767-777. PubMed ID: 33044426
    [Abstract] [Full Text] [Related]

  • 3. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.
    Koss CA, Havlir DV, Ayieko J, Kwarisiima D, Kabami J, Chamie G, Atukunda M, Mwinike Y, Mwangwa F, Owaraganise A, Peng J, Olilo W, Snyman K, Awuonda B, Clark TD, Black D, Nugent J, Brown LB, Marquez C, Okochi H, Zhang K, Camlin CS, Jain V, Gandhi M, Cohen CR, Bukusi EA, Charlebois ED, Petersen ML, Kamya MR, Balzer LB.
    PLoS Med; 2021 Feb; 18(2):e1003492. PubMed ID: 33561143
    [Abstract] [Full Text] [Related]

  • 4. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
    van Vliet MM, Hendrickson C, Nichols BE, Boucher CA, Peters RP, van de Vijver DA.
    J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
    Reidy M, Gardiner E, Pretorius C, Glaubius R, Torjesen K, Kripke K.
    PLoS One; 2019 Dec; 14(6):e0218710. PubMed ID: 31242240
    [Abstract] [Full Text] [Related]

  • 8. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa.
    Jamieson L, Gomez GB, Rebe K, Brown B, Subedar H, Jenkins S, Shoko N, Bekker LG, Johnson LF, Meyer-Rath G.
    AIDS; 2020 May 01; 34(6):883-891. PubMed ID: 32004205
    [Abstract] [Full Text] [Related]

  • 9. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
    Grulich AE, Guy R, Amin J, Jin F, Selvey C, Holden J, Schmidt HA, Zablotska I, Price K, Whittaker B, Chant K, Cooper C, McGill S, Telfer B, Yeung B, Levitt G, Ogilvie EE, Dharan NJ, Hammoud MA, Vaccher S, Watchirs-Smith L, McNulty A, Smith DJ, Allen DM, Baker D, Bloch M, Bopage RI, Brown K, Carr A, Carmody CJ, Collins KL, Finlayson R, Foster R, Jackson EY, Lewis DA, Lusk J, O'Connor CC, Ryder N, Vlahakis E, Read P, Cooper DA, Expanded PrEP Implementation in Communities New South Wales (EPIC-NSW) research group.
    Lancet HIV; 2018 Nov 01; 5(11):e629-e637. PubMed ID: 30343026
    [Abstract] [Full Text] [Related]

  • 10. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project.
    Celum CL, Bukusi EA, Bekker LG, Delany-Moretlwe S, Kidoguchi L, Omollo V, Rousseau E, Travill D, Morton JF, Mogaka F, O'Malley G, Barnabee G, van der Straten A, Donnell D, Parikh UM, Kudrick L, Anderson PL, Haberer JE, Wu L, Heffron R, Johnson R, Morrison S, Baeten JM, POWER Study Team.
    J Int AIDS Soc; 2022 Jul 01; 25(7):e25962. PubMed ID: 35822945
    [Abstract] [Full Text] [Related]

  • 11. Combined interventions to reduce HIV incidence in KwaZulu-Natal: a modelling study.
    Blaizot S, Huerga H, Riche B, Ellman T, Shroufi A, Etard JF, Ecochard R.
    BMC Infect Dis; 2017 Jul 26; 17(1):522. PubMed ID: 28747167
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Strengthening health system's capacity for pre-exposure prophylaxis for adolescent girls and young women and adolescent boys and young men in South Africa (SHeS'Cap-PrEP): Protocol for a mixed methods study in KwaZulu-Natal, South Africa.
    Nicol E, Ramraj T, Hlongwa M, Basera W, Jama N, Lombard C, McClinton-Appollis T, Govindasamy D, Pass D, Funani N, Aheron S, Paredes-Vincent A, Drummond J, Cheyip M, Dladla S, Bedford J, Mathews C.
    PLoS One; 2022 Jul 26; 17(3):e0264808. PubMed ID: 35298487
    [Abstract] [Full Text] [Related]

  • 15. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries.
    Pretorius C, Schnure M, Dent J, Glaubius R, Mahiane G, Hamilton M, Reidy M, Matse S, Njeuhmeli E, Castor D, Kripke K.
    J Int AIDS Soc; 2020 Feb 26; 23(2):e25451. PubMed ID: 32112512
    [Abstract] [Full Text] [Related]

  • 16. Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial.
    Beesham I, Welch JD, Heffron R, Pleaner M, Kidoguchi L, Palanee-Phillips T, Ahmed K, Baron D, Bukusi EA, Louw C, Mastro TD, Smit J, Batting JR, Malahleha M, Bailey VC, Beksinska M, Donnell D, Baeten JM, ECHO Trial Consortium.
    J Int AIDS Soc; 2020 May 26; 23(5):e25491. PubMed ID: 32396700
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.